Novo Cuts Outlook, Pledges Crackdown On Copycat Obesity Drugs [zero hedge]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: zero hedge
Novo Cuts Outlook, Pledges Crackdown On Copycat Obesity Drugs Novo Nordisk shares surged as much as 6.5% in European trading, making it a top performer on the Stoxx 600, as Wall Street analysts said the Danish drugmaker's guidance cut was largely priced in—and pressures on Wegovy sales from compounded anti-obesity drugs may soon ease. Investor sentiment was also buoyed by expectations that Wegovy sales, will rebound in the second half, as the availability of compounded copycat versions declines. "We have reduced our full-year outlook due to lower-than-planned branded GLP-1 penetration, which is impacted by the rapid expansion of compounding in the U.S. We are actively focused on preventing unlawful and unsafe compounding and on efforts to expand patient access to our GLP-1 treatments," Novo CEO Lars Fruergaard Jorgensen wrote in a statement. Jorgensen told CNBC in an interview earlier, "Compounders took a part of our business away," adding, "We now expect that compounding will be knoc
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Assessing Novo Nordisk After Recent Volatility and Debate Over Obesity Drug Pricing [Yahoo! Finance]Yahoo! Finance
- Novo Nordisk (NVO) Rises Higher Than Market: Key Facts [Yahoo! Finance]Yahoo! Finance
- Omeros: Stock Pops On Yartemlea Approval, Longer-Term Upside Likely [Seeking Alpha]Seeking Alpha
- FDA approves Novo Nordisk's weight-loss pill [FOX Business Network]FOX Business Network
- Novo Nordisk: The Real Comeback Starts Now With The Wegovy Pill [Seeking Alpha]Seeking Alpha
NVO
Earnings
- 11/6/25 - Beat
NVO
Sec Filings
- 12/23/25 - Form 6-K
- 11/25/25 - Form 6-K
- 11/24/25 - Form 6-K
- NVO's page on the SEC website